Objectives To compare vancomycin dosage adjustment by evaluating trough concentrations (Ctrough) of vancomycin and its pharmacokinetic/pharmacodynamic (PK/PD) correlation (AUC/MIC ≥400). Methods A retrospective study of 52 adult haematological patients and 29 ICU patients was carried out. Dosage adjustment was performed in routine clinical practice with Ctrough and then compared using a PK/ PD model. The probability of achieving the PK/PD target associated with the success of antimicrobial therapy was evaluated. When the susceptibility of the organism responsible for infection is not known, Monte Carlo simulation calculates the cumulative fraction of response (CFR) from the distribution of MIC values. Values of CFR >90% represent an optimal achieved regimen against a population of microorganisms. results According to dosage adjustment performed with Ctrough, in haematological patients the dose of vancomycin was increased in 65.4% compared with an increase in 53.8% of patients with the PK/PD model. No dose adjustment was needed in 21.1% of patients using Ctrough compared with 7.7% with the PK/PD model and in 13.5% of patients using Ctrough determination and in 38.5% of patients with the PK/PD model the dose was reduced. For ICU patients the dosage adjustment made with Ctrough resulted in an increased dose of vancomycin in 79.4% of patients compared with 41.4% with the PK/PD model. No dose adjustment was needed in 3.4% of patients using Ctrough in comparison with 13.8% with the PK/PD model, and the dose was reduced in 17.2% of patients using Ctrough determination and in 44.8% with the PK/PD model. Conclusions Data for bacterial susceptibility combined with measured data for antibiotic concentrations using a PK/PD model predict and improve the dosage adjustment for individual patients. A larger study with more complete datasets are needed for validation before it can be fully introduced into clinical practice.
A rational and correct use of antibiotics can help to reduce mortality and morbidity related to infections. The wrong dose of antimicrobials may be responsible for a higher therapeutic failure rate, higher mortality and toxicity, greater costs and increased resistance. In general terms, adequate antibiotic therapy is defined as the therapeutic regimen with demonstrated in vitro activity against the causative organism. 1 However, the microorganism susceptibility profile does not give us the most appropriate dosage. This is due to the fact that therapeutic success of antibiotic therapy is multifactorial and depends on the interaction between the drug and the pathogen and also its virulence, the host's immune system as well as the site of infection. Therefore, the success of an antibiotic treatment is conditioned by adequate drug selection and by the dosage regimen used. Pharmacodynamics describe the interaction between the concentration of a drug at the site of infection and the minimal inhibitory concentration (MIC) of the microorganism. The knowledge of this interaction is what enables us to calculate the correct dosage of an antibiotic showing a bactericidal effect against the pathogen and a favourable clinical response minimising adverse effects. Optimal antibiotherapy is therefore defined as 'the antimicrobial selection and appropriate dosing regimen getting the best clinical results with minimal side effects for the patient and with minimal development of resistance'. 1 Thus, therapeutic success of antimicrobial therapy depends on three parameters: the patient, the antibiotic and the microorganism. The objective of a pharmacokinetic/pharmacodynamic (PK/ PD) model is to link these three parameters. The relationship between the patient and the antibiotic is defined by the pharmacokinetic model (PK), including PK parameters and their factors of variability. On the other hand, the relationship between the antibiotic and the microorganism is given by in vitro susceptibility to drugs -MIC, known as the pharmacodynamic model (PD). The PK/PD model was constructed combining the two individual models. 1 Vancomycin is one of the standard antibacterial drugs used against methicillin-resistant Staphylococcus aureus (MRSA). Patients admitted to intensive care units (ICUs) often require antibiotic therapy to treat complicated infections. More than 70% of S. aureus isolated in ICUs are resistant to methicillin, and vancomycin has long been the gold standard treatment for presumed or confirmed infections caused by this pathogen. 2 It is still often employed in patients with malignant haematological disease as empirical treatment for febrile neutropenia. 3 4 In this critical population, inadequate antibacterial treatment results in increased mortality and infection-related morbidity. Dosage recommendations for this antibiotic are 15 mg/ kg every 8 or 12 hours, but usually this dosage individualisation is not performed and a standard dosage of 1000 mg every 12 hours is administered to most patients, regardless of weight or renal function. The therapeutic objective in clinical practice is to obtain trough plasma concentrations (Ctrough) of 10-15 μg/mL for empirical treatment and 15-20 μg/mL in severe infections. [5] [6] [7] [8] [9] [10] [11] In recent years, area under the inhibitory curve (AUC) dosage adjustment has been increasingly promoted as an alternative to the vancomycin dosing method, which is based on the fact that vancomycin is a non-concentration-dependent antibiotic. Its bactericidal activity does not depend on achieving high peak concentration levels. It kills more effectively when the pathogen is exposed to concentrations greater than the MIC value for an extended period of time. For this reason, AUC dosage adjustment has been adapted to incorporate this bactericidal power against the pathogen in the form of 'area under the inhibitory curve', which is more commonly represented as AUC/MIC. The AUC is the daily dose (D) (in milligrams) divided by vancomycin clearance (Clv) (in litres/hour). As the MIC of the pathogen rises, a greater AUC, and therefore a larger daily dose, is called for treatment. 12 However, trough concentrations are just a surrogate variable of AUC. For example, trough levels of 10 μg/mL are correlated with an AUC of 250. Nevertheless, AUC/MIC values are considered to predict time-related clinical and bacteriological outcomes. 8 AUC/MIC ≥400 has been considered as the PK/PD efficacy index. On the other hand, an AUC of 700 is also considered as the breakpoint best associated with an increased risk of nephrotoxicity. 13 This report deals with the important aspect of optimising therapeutic drug monitoring of vancomycin and whether or not the standard Ctrough measurements should be replaced by AUC/ MIC. The hypothesis of this study is based on the fact that, with AUC/MIC determination, more precise dosage adjustments are achieved, avoiding unnecessary excessive doses and their related adverse effects.
The aim of our study is to compare vancomycin dosage adjustment in ICU patients with complicated infections and haematological patients with empirical antimicrobial therapy in febrile neutropenia by evaluating trough concentrations of vancomycin (10-15 μg/mL and 15-20 μg/mL, respectively) and the PK/PD correlation (AUC/MIC ≥400).
MATerIAl And MeThOds Patients and study design
A retrospective observational pilot study was carried out using data from common clinical practice over a period of 2 years (2013-2014), including adult patients with an underlying haematological malignancy and ICU patients with complicated infections who were admitted to the Haematology Unit and ICU of the Hospital General Universitario de Castellón (a 560-bed University Hospital), and were all receiving vancomycin therapy for a suspected infection caused by Gram-positive bacteria. These patients had undergone vancomycin plasma level determinations for controlling and monitoring treatment. Sampling was performed 15-30 min before the next dose of vancomycin and after the third administration of the initial dose of antibiotic, according to our protocol. Vancomycin plasma concentrations were measured by fluorescence polarisation immunoassay (Architect; Abbott Laboratories, Abbott Park, Illinois, USA). The external quality control used was Unity (Bio-Rad Laboratories).
Pharmacokinetic analysis
In daily clinical practice and in order to achieve our Ctrough objective, the vancomycin dosage was adjusted by Bayesian estimation using biometric features of the patient (age, sex, weight and creatinine clearance) from the Pks program version 1.10 (Abbottbase Pharmacokinetic System), considering the pharmacokinetics of vancomycin as a one-compartment model. Our therapeutic objective was to obtain 10-15 μg/mL in empirical treatment and 15-20 μg/mL in complicated infections. The time response between the results of the determinations from the Pharmacokinetics Unit to the clinician was less than 3 hours, and dosage adjustments were usually based on these results. Dosage adjustment was made in routine clinical practice with the PK model and then compared with the dosage adjustment using the PK/PD model.
A retrospective study was performed collecting data of dosage adjustment by pharmacokinetic modelling. Demographic data of patients, vancomycin dosage and therapy and plasma concentrations were obtained from the database of the Clinical Pharmacokinetics Unit of the hospital, which included the precise timing of drug dosing and blood sampling. These data derived from therapeutic drug monitoring laboratory requests and were validated and accurate for each included sample. They also included age and sex of the patient, creatinine values, dosing regimen, Ctrough obtained and dosage adjustment recommendation made by the pharmacist. These data were collected in an Excel spreadsheet. Clv was calculated for each patient by Bayesian estimation using the Pks program. Patient consent was not required because we only compared the dosage adjustment recommendation made with what could have been recommended if this new method had been used.
Pharmacodynamic analysis
The distribution of MIC for MRSA in 2013 and 2014 in our environment was given by the Microbiology Department of the Hospital. The method used for determining the MIC was an automated microdilution system (PhoenixBD) and every MIC >1 for vancomycin was confirmed by E-test (BioMerieux). This distribution was expressed as a percentage and a discrete variable for further analysis was considered.
Pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation
The exact MIC for the microorganism is not known because we do not have an isolated pathogen, so we need to use the MIC distribution in our environment for dose adjustment by the PK/ PD model. For this reason, we used the mathematical tool known as Monte Carlo simulation to generate random figures which were used to link MIC data with PK profiles to predict the probability of a certain therapeutic outcome (AUC/MIC ≥400).
14 For empirical treatment, when the susceptibility of the organism responsible for the infection is not known, Monte Carlo simulation calculates the cumulative fraction of response (CFR) from the distribution of MIC values. 1 Values of CFR >90% represent an optimal regimen achieved against a population of microorganisms. Another computation is the probability of target attainment, which is defined as the probability that at least a specific value of PK/PD is achieved at a certain MIC. 15 16 Monte Carlo simulation consists of assigning probability distributions to model variables that involve risk and then generating random numbers based on those distributions in order to simulate the behaviour of the modelled problem we will have in the future. By using this, it is possible to obtain more realistic Original article 
Figure 1
Comparison of dose modification with the PK/PD model (AUC/MIC) and the PK model (Ctrough) in haematology patients; x axis, increase or decrease in dose (mg); y axis, number of patients.
and reliable results when making decisions. Monte Carlo simulation was performed using the SimulAr program (http://www. simularsoft. com. ar/). 17 SimulAr is a simulation software designed to analyse, evaluate and make decisions within the context of risk. We defined as 'inputs' for this software: the daily dose of the patient (D), which is a constant, the Clv and MIC distribution. Clv was expressed as a mean and a variability of 20% was established (SD). A log-Gaussian distribution was assumed for Clv data, and the average and SD calculations were transformed into the logarithmic form. 18 D divided by Clv allows us to calculate AUC. We then defined the 'output': AUC/MIC. The ultimate goal was AUC/MIC ≥400. Monte Carlo simulation was used to calculate the probability of achieving this objective, performing for 10 000 iterations in each case. It calculates the probability index that exceeds the target value related to treatment efficacy (≥400). This probability index is the CFR >90%.
Simulations for 500 mg/day as well as higher dosages (up to 10 000 mg/day) were performed in order to predict the outcome of increasing (or decreasing) the daily doses in this population group, until achieving a CFR >90%. This dosage adjustment was compared with that using only clinical PK parameters (Ctrough) with the Pks software. This comparison was obtained by performing a contingency table and calculating the difference by Pearson χ 2 , because it was a non-parametric statistical comparison between qualitative variables. A Mann-Whitney test was performed to calculate the significance of the magnitude analysis of the modified doses because of non-normal distribution of the population, and this was shown as a boxplot. A p value of 0.05 was considered to indicate a statistically significant association.
resulTs
During the study period from January 2013 to December 2014 we evaluated 52 adult haematological patients (57% male) treated with vancomycin as empirical treatment for fever and neutropenia. Vancomycin doses were infused intravenously for 60 min. The initial dose was 1000 mg/12 hours for all patients. During the same period 29 ICU patients (58.6% male) treated with vancomycin for complicated infections were also evaluated. The initial dose was 1000 mg/12 hours for 58.7% of the patients, 27.6% of patients had an initial dose of 1000 mg every 8 hours and the remaining 13.7% were started on other doses (table 1) .
The MIC distribution for MRSA at our hospital in 2013-2014 was as follows: 37.6% of isolates were MIC=0.5; 60.5% MIC=1; 0.08% MIC=1.5; and 1.82% MIC=2.
In order to quantify the differences between the dosage adjustment using PK analyses and a PK/PD model, we obtained the AUC/MIC ratio by Monte Carlo simulation for the whole population studied for vancomycin dosages between 500 and 10 000 mg/day. Figure 1 and figure 2 show a comparison of how the doses increase or decrease with the two methods. It can be seen that the dose is reduced in more patients using the PK/PD model (AUC/MIC) than in those using the PK model (Ctrough), and it increased in more patients using the PK model.
According to the dosage adjustment performed with Pks software, the dose of vancomycin in haematological patients was increased in 65.4% using Ctrough and in 53.8% with the PK/ PD model. No dose adjustment was needed in 21.1% of patients using Ctrough compared with 7.7% with the PK/PD model. The dose was reduced in 13.5% of patients using Ctrough determination and in 38.5% with the PK/PD model. Recommendations for dosage adjustment made with the two methods were statistically significant (p=0.006), so we tend to recommend lower doses with the PK/PD model. For ICU patients the dosage adjustment made with Ctrough increased the dose of vancomycin in 79.4% of the patients compared with 41.4% with the PK/PD model. No dose adjustment was needed in 3.4% of patients using Ctrough compared with 13.8% with the PK/PD model. The dose was reduced in 17.2% of patients using Ctrough determination and in 44.8% with the PK/PD model. Recommendations for dosage adjustment made with both methods were statistically significant (p=0.012), so we also tend to recommend lower doses with the PK/PD model.
A magnitude analysis of the modified dose was also performed. Comparison between the two methods was made in both increasing and decreasing doses.
In haematological patients the PK model recommended a median (range) increase of 1000 mg (−1000, 4000) whereas, with the PK/PD method, the dose was increased by 250 mg (−1000, 2000) (p=0.006, Mann-Whitney test). In ICU patients the PK model recommended a median (range) increase of 1000 mg (−2500, 7500) whereas, with the PK/PD setting, the dose was increased by 0 mg (−3250, 2750) (p=0.003, MannWhitney test). The boxplots in figure 3 and figure 4 show a lower dose reduction with the PK/PD model and also a lower dose increase in haematology and ICU patients.
We also performed another analysis comparing the two methods of data obtained from vancomycin exposure of patients to three doses: initial dose, PK dose and PK/PD dose for an organism for which the MIC is 1 mg/L. The results of the analysis are shown in table 2.
In haematological patients the initial dose was ineffective in 42.3% of the patients, obtaining an AUC <400, whereas only 1.9% of patients received an initial ineffective dose with the PK model. The proportion of profiles with AUC 700, considered as an increased risk of nephrotoxicity, was 11.5% of patients with the initial dose, 9.6% of patients with the calculated PK dose and only 5.7% of patients with the PK/PD model.
Comparing the two models, we obtained important data that would lead to disagreements in the adjustment: 28.8% of patients with Ctrough <10 μg/mL obtained an AUC ≥400. On the other hand, 7.7% and 11.5% of patients with Ctrough >15 μg/mL obtained an AUC <400 and AUC 400-700, respectively.
In ICU patients the initial dose was ineffective with an AUC <400 in 37.9% of patients. The proportion of patients with AUC ≥700 was 27.6% with the initial dose, 58.6% with the calculated PK dose and 6.9% with the PK/PD model.
Comparing the two models, 41.1% of patients with Ctrough <15 μg/mL obtained an AUC ≥400. In addition, 12.5% of patients with Ctrough <15 μg/mL had an AUC >700.
dIsCussIOn
Inappropriate antibiotic treatment is likely to result in a higher clinical failure rate, higher mortality, greater costs, increased toxicity and increased resistance. Thus, the use of an optimised dosing regimen that guarantees an optimal concentration of vancomycin at the infection site is essential to achieve the best clinical outcome. 15 The increasing MICs of staphylococcal Original article organisms now demand maximal antibiotic efficacy from modified dosing regimens, 19 20 especially those patients in whom early and appropriate antibiotic therapy is a key factor for improving the clinical outcome. Pharmacokinetics could be an important constituent of antibiotic efficacy by predicting drug exposure, but pharmacodynamic goals and pathogen susceptibility must also be considered to ensure clinical efficacy. Several PK/PD indexes have emerged as markers for successful clinical outcomes of antibiotic therapy, and they combine patient-specific PK parameters and their variability with specific susceptibility data concerning the strain of microorganism in question. 21 The application of population kinetics with PK/PD analysis based on Monte Carlo simulation is an excellent tool for defining dosage strategies aimed at estimating the likelihood that the antibiotic will effectively treat a specific cohort of patients. 22 In this regard, Monte Carlo simulation can be used as a statistical tool for estimating how selected AUC/MIC values influence the CFR associated with vancomycin efficacy. 15 The local MIC distribution must be taken into account and must be updated periodically because of the emergence of regional drug resistance and the huge regional differences in MIC distributions.
In this study we first obtained and validated vancomycin population PK parameters in two representative groups of patients (haematology and ICU). We then assessed their CFR with MIC ranging from 0.5 to 2 using several doses of vancomycin by PK/ PD analysis and Monte Carlo simulation. The corresponding CFR value varied significantly according to the different doses. To quantify the differences between dosages using PK analyses versus the PK/PD model, we obtained the AUC/MIC ratio for the whole population. It was observed that differences in dosage adjustment recommendations made with the two methods were statistically significant, and we tend to recommend lower doses using the PK/PD model. Furthermore, the analysis in magnitude shows us that the increases in vancomycin dosage are smaller and less variable for both populations when using the PK/PD adjustment.
Although the evaluation of the Ctrough may be a suboptimal method for assessing the adequacy of a vancomycin dose, % (n) patients with AUC ≥400 and Ctrough <10 μg/mL 28.8 (15) % (n) with Ctrough >15 μg/mL and AUC of: current guidelines for monitoring vancomycin treatment still recommend such an approach and suggest that Ctrough should always be maintained above 10 mg/mL to avoid the development of resistance and, for complicated infections, in the range of 15-20 mg/mL to improve clinical outcomes. For a pathogen with an MIC of 1 mg/mL, these trough recommendations are able to guarantee the target AUC/MIC ≥400, 21 but the fact is that, when the real MIC value is known, it is possible to calculate and adjust the dose with a PK/PD model to reach the desired target.
By carefully analysing the data we found that, for haematology patients, in 42.3% of cases (n=22) the initial dose given was considered ineffective using the PK/PD model (AUC <400). There was a risk of nephrotoxicity in 11.5% (n=6) of patients with initial doses and in 9.6% (n=5) after PK adjustment. The PK adjustment would leave 7.7% (n=4) of patients with suboptimal doses (Ctrough >15 mg/mL, AUC <400). In these patients, the tendency would be to decrease the dose using the PK model when it is not really near nephrotoxicity, even though it would reduce the effectiveness according to the PK/PD model. Fifteen patients (28.8%) were overdosed (Ctrough <10 mg/mL and AUC ≥400), which could result in unnecessary increased doses and a risk of toxicity. In ICU patients, in 37.9% (n=11) the initial dose given was considered ineffective. There was a risk of nephrotoxicity in 27.6% (n=8) of the patients with initial doses and 58.6% (n=17) after PK adjustment. The PK adjustment overdosed 41.4% (n=12) of patients (Ctrough <15 mg/mL and AUC >400) and in one patient (12.5%) increased the dose to an AUC >700, increasing the risk of nephrotoxicity.
Thus, it was observed that AUC of the initial dose used in practice is close to the therapeutic target with PK/PD but, in both groups of patients, the initial dose is not considered effective in approximately 40% (37.9-42.3%) and is possibly nephrotoxic in 11.5% and 27.6% of patients. Therefore, we can conclude that there is a greater variability in the AUC obtained at the initial dose, in which we are not interested. 28.8% and 41.4% of adults with normal renal function and a therapeutic AUC of ≥400 for a microorganism whose MIC for vancomycin is 1 mg/L are expected to have a Ctrough below the suggested minimum target of 10 or 15 μg/mL. Our data indicate that many adults can have an adequate vancomycin AUC with a Ctrough of <10 or 15 μg/mL. Increasing those patients' dose to achieve a Ctrough of 10-15 μg/mL will needlessly raise the AUC and increase the risks of renal injury. 23 Some limitations of this study should be considered: ► Dosage adjustment with the PK model was performed prospectively in clinical practice and applied following the recommendations made by the pharmacist. On the other hand, the PK/PD analysis was performed retrospectively and not applied in practice on these patients. ► The study was made using a distribution of MICs in our environment during a 2-year period, calculating the CFR. Values of CFR >90% represent an optimal regimen against a population of microorganisms. However, another computation is the probability of target attainment, which is defined as the probability that at least a specific value of PK/PD is achieved at a certain MIC. If it were possible to get the exact MIC of each patient at the time of analysis, a more accurate dosage adjustment could be obtained using the PK/PD model. As an alternative, it was proposed that the Department of Microbiology perform an E-test on samples of ICU patients to obtain their MIC in only 24 hours in order to better calculate the dosage regimen of vancomycin. ► Bayesian Cl estimation is only performed with the first pharmacokinetic monitoring of each patient. The reason for this is that CL was only performed from one Ctrough value, which is the only available data in clinical practice at the moment, so there were not enough plasma level determinations available for the same patient and consequently plasma level concentrations show a lower predictive power. This is a major limitation for a first study of a new method and, for that reason, we do not know whether we can fully trust the results. It would be interesting to develop this study with a more accurate estimation of each patient's clearance. Also, it would be convenient to have two or more measurements of blood vancomycin concentration.
Original article
► The sample size is limited. One of the reasons for this is the limited use of vancomycin. Although it is the treatment of choice for Gram-positive organisms including Staphylococcus coagulase negative and MRSA, there are other alternative treatments, especially when dealing with persistent bacteria. Given the difficulty of obtaining a larger number of samples, it is necessary to carry out larger multicentre studies that would increase the number of patients so that we can make more accurate estimations. Prospective experiments including pharmacokinetic analyses, antimicrobial susceptibility and clinical data are essential and can help to accurately determine correlations between dosage adjustments with the PK/PD model and clinical outcomes. 15 
COnClusIOn
In this study we have compared vancomycin dosage adjustments in haematological and ICU patients by evaluating trough concentrations of vancomycin and the PK/PD correlation. It was observed that differences in dosage adjustment recommendations made with the two methods were statistically significant, and we tend to recommend lower doses when using the PK/PD model. It was also observed that AUC of the initial dose used in practice is close to the therapeutic target PK/PD, but the initial dose is not considered effective in approximately 40%. We therefore conclude that there is greater variability in the AUC obtained at the initial dose.
Based on the present findings and limitations, we conclude that data for bacterial susceptibility combined with measured data for antibiotic concentrations using PK/PD models predict dosage adjustment for individual patients, increasing the probability of clinical success of the antimicrobial treatment. These preliminary data obtained show enough evidence to design a larger study to validate the PK/PD model for vancomycin and to be able to adjust its dosages in clinical practice. A larger study with more complete datasets is needed for validation before it can be fully introduced into clinical practice.
What this paper adds
What is already known on this subject ► When administerting any antibiotic it is very important to have information about the infection, the responsible microorganism and the characteristics of the patient. The more and better information collected, the better individualised dosage adjustment can be achieved. ► At present at our hospital the Pharmokinetics Unit of the Pharmacy Department provides pharmacokinetic adjustment of vancomycin by measuring blood levels. ► The pharmacodynamic aspect (susceptibility of the microorganism) is not used when setting the dose of an antibiotic.
What this study adds ► This study shows the possibility of including pharmacodynamic parameters in the prediction of the best dosage of vancomycin for a specific patient with a specific infection and, thus, improving drug effectiveness and reducing the occurrence of resistance.
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